➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Express Scripts
Dow
Boehringer Ingelheim
Harvard Business School

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 7,049,133

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,049,133
Title:Regulation of gene expression through manipulation of mRNA splicing and its uses
Abstract: A cis-acting nucleotide sequence which is capable of rendering the removal of introns from a precursor transcript encoded by a gene, which gene harbors at least one such cis-acting nucleotide sequence, occurring during the production of mRNA of a gene, dependent upon activation of a trans-acting factor. The trans-acting factor is an RNA-activated protein kinase which is capable of phosphorylating the .alpha.-subunit of eukaryotic initiation factor 2. The trans-acting factor is preferably, the RNA-activated protein kinase (PKR). The cis-acting nucleotide sequence can be derived from the 3\' untranslated region of the human tumor necrosis factor .alpha. gene (TNF-.alpha.3\'-UTR) and may comprise the nucleotide sequence as denoted by SEQ ID NO:1 or biologically functional fragments, derivatives, mutants and homologues thereof.
Inventor(s): Kaempfer; Raymond (Jerusalem, IL), Osman; Farhat (Sakhnin, IL), Jarrous; Nayef (Shefaram, IL), Ben-Asouli; Yitzhak (Kfar Hanagid, IL)
Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL)
Application Number:09/801,371
Patent Claims:see list of patent claims

Details for Patent 7,049,133

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL) 2018-09-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL) 2018-09-07 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL) 2018-09-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Dow
McKinsey
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.